Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.72 - $34.47
Previous CloseN/A
Volume171.97K
Average Volume (3M)2.35M
Market Cap
$2.42B
Enterprise Value$3.26B
Total Cash (Recent Filing)$374.69M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta0.90
Next Earnings
May 28, 2025EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.62
Shares Outstanding169,860,690
10 Day Avg. Volume2,160,800
30 Day Avg. Volume2,349,008
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.13K
Enterprise Value/Ebitda-8.06
Forecast
1Y Price Target
$47.09Price Target Upside230.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Immunovant News
PremiumCompany Announcements
Immunovant Announces New CEO Amid Strategic Shift
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentA potentially registrational program in Sjögren’s disease is expected to kick off, indicating progress in clinical development.
Operational StrategyImmunovant announced leadership changes with new executives, which could enhance operational control and strategic decisions.
Strategic ExpansionThe selection of two new indications for lead asset IMVT-1402 – Sjogren’s disease and cutaneous lupus erythematosus – is viewed as logical and attractive expansion opportunities.
Bears Say
Financial ConcernsAnnualized cash burn is $345 million, suggesting substantial ongoing expenses that could impact financial stability.
Market SkepticismShort interest stands at 28.9% of the float, indicating a significant amount of skepticism or bearish sentiment among investors.
Product ChallengesConcerns exist about the safety risk of bato compared to competitors, which could limit its adoption in the market.
---
Ownership Overview
2.73% Insiders
15.46% Mutual Funds
24.73% Other Institutional Investors
49.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $34.47 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $2.42B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is May 28, 2025 which is in 34 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 06, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.752 by -$0.008.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.71.
How many shares outstanding does Immunovant have?
Immunovant has 169,860,690 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.752. Following the earnings report the stock price went down -9.551%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
---
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.09 (230.46% Upside)
$47.09 (230.46% Upside)
Blogger Sentiment
Neutral
IMVT Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.49%
12-Months-Change
Fundamentals
Return on Equity
-74.17%
Trailing 12-Months
Asset Growth
-40.83%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
---
IMVT Stock 12 Month Forecast
Average Price Target
$47.09
▲(230.46% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crispr Therapeutics AG
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+69.76%
reiterated a buy rating 4 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +69.76% per trade.
---